KalVista Pharmaceuticals (KALV) Free Cash Flow (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Free Cash Flow of -$54.8 million for Q3 2025, down 36.01% on a YoY basis from -$85.6 million in Q3 2024, and down 35.17% sequentially from -$40.5 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Free Cash Flow (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Free Cash Flow data on file, last reported at -$54.8 million in Q3 2025.
- For the quarter ending Q3 2025, Free Cash Flow fell 36.01% year-over-year to -$54.8 million; the trailing twelve-month figure through Jul 2025 stood at -$135.0 million (down 31.33% YoY), and the FY2025 full-year result was -$153.3 million, down 71.77% from the prior year.
- Free Cash Flow retreated to -$54.8 million in Q3 2025, from -$40.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$7.6 million in Q1 2021 to a low of -$54.8 million in Q3 2025.
- A 5-year average of -$24.4 million and a median of -$21.7 million in 2022 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 42.02% in 2021, while the deepest fall reached 399.22% in 2021.
- Tracing KALV's Free Cash Flow over 5 years: stood at -$19.9 million in 2021, then slipped by 4.45% to -$20.8 million in 2022, then increased by 4.61% to -$19.8 million in 2023, then plunged by 100.27% to -$39.7 million in 2024, then slumped by 37.99% to -$54.8 million in 2025.
- Business Quant data shows KALV's Free Cash Flow at -$54.8 million in Q3 2025, -$40.5 million in Q2 2025, and -$39.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -54.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -54.79 Mn |
| Jul 31, 2025 | -54.79 Mn |
| Apr 30, 2025 | -40.54 Mn |
| Apr 30, 2025 | -40.54 Mn |
| Oct 31, 2024 | -39.71 Mn |
| Oct 31, 2024 | -39.71 Mn |
| Jul 31, 2024 | -40.28 Mn |
| Jul 31, 2024 | -40.28 Mn |
| Apr 30, 2024 | -14.85 Mn |
| Apr 30, 2024 | -14.85 Mn |
| Jan 31, 2024 | -27.86 Mn |
| Jan 31, 2024 | -27.86 Mn |
| Oct 31, 2023 | -19.83 Mn |
| Oct 31, 2023 | -19.83 Mn |
| Jul 31, 2023 | -26.74 Mn |
| Jul 31, 2023 | -26.74 Mn |
| Apr 30, 2023 | -22.71 Mn |
| Apr 30, 2023 | -22.71 Mn |
| Jan 31, 2023 | -9.30 Mn |
| Jan 31, 2023 | -9.30 Mn |